These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29720487)

  • 1. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
    Ceriani L; Milan L; Martelli M; Ferreri AJM; Cascione L; Zinzani PL; Di Rocco A; Conconi A; Stathis A; Cavalli F; Bellei M; Cozens K; Porro E; Giovanella L; Johnson PW; Zucca E
    Blood; 2018 Jul; 132(2):179-186. PubMed ID: 29720487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
    Ceriani L; Martelli M; Zinzani PL; Ferreri AJ; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Gargantini L; Merli F; Pinotti G; Mannina D; Luminari S; Stathis A; Russo E; Cavalli F; Giovanella L; Johnson PW; Zucca E
    Blood; 2015 Aug; 126(8):950-6. PubMed ID: 26089397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
    Ceriani L; Martelli M; Conconi A; Zinzani PL; Ferreri AJM; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Giovanella L; Zucca E; Johnson PWM
    Br J Haematol; 2017 Aug; 178(4):588-591. PubMed ID: 28485042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
    Zhang YY; Song L; Zhao MX; Hu K
    Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 7. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.
    Pinnix CC; Ng AK; Dabaja BS; Milgrom SA; Gunther JR; Fuller CD; Smith GL; Abou Yehia Z; Qiao W; Wogan CF; Akhtari M; Mawlawi O; Medeiros LJ; Chuang HH; Martin-Doyle W; Armand P; LaCasce AS; Oki Y; Fanale M; Westin J; Neelapu S; Nastoupil L
    Blood Adv; 2018 Jun; 2(11):1334-1343. PubMed ID: 29895624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
    Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
    Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-Therapeutic Total Lesion Glycolysis on [
    Mayerhoefer ME; Staudenherz A; Kiesewetter B; Weber M; Simonitsch-Klupp I; Gibbs P; Dolak W; Lukas J; Raderer M
    Mol Imaging Biol; 2019 Dec; 21(6):1192-1199. PubMed ID: 30847823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can metabolic tumor parameters on primary staging
    Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.
    Ceriani L; Milan L; Johnson PWM; Martelli M; Presilla S; Giovanella L; Zucca E
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1334-1344. PubMed ID: 30806751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative FDG-PET: a new biomarker in PMBCL.
    Meignan M
    Blood; 2015 Aug; 126(8):924-6. PubMed ID: 26294712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.
    Senjo H; Hirata K; Izumiyama K; Minauchi K; Tsukamoto E; Itoh K; Kanaya M; Mori A; Ota S; Hashimoto D; Teshima T;
    Blood Adv; 2020 May; 4(10):2286-2296. PubMed ID: 32453838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.